Findings

What do systematic reviews say?

4 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 40%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 0 · 0%High 0 · 0%

PDEI vs placebo

Adverse events

PDEI may leads to higher adverse events compared with placebo (low certainty).

1 finding from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
RR 1.42 [1.21, 1.67]
11 studies · 4386 participants
Low

PDEI vs alpha‐blocker

Adverse events

PDEI showed no clear difference in adverse events compared with alpha‐blockers (low certainty).

1 finding from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
RR 1.35 [0.8, 2.3]
4 studies · 786 participants
Low

PDEI + 5‐ARI vs 5‐ARI alone

Adverse events

The review found no eligible studies for this question.

2 findings from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
RR 1.07 [0.84, 1.36]
1 study · 695 participants
Low

PDEI plus alpha‐blocker vs PDEI alone

Adverse events

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found